Valeant Pharmaceuticals said on Tuesday it would reorganize, and stood by its full-year forecast, as it attempts to restore investor confidence after facing a storm of criticism over its business practices. Excluding items, Valeant earned $1.40 per share, missing analysts' average estimate of $1.48. Valeant, which has about $30.77 billion US in debt, also had to appease creditors after missing deadlines for filing financial reports, triggering default notices. The company reports in U.S. dollars. Revenue fallsThe company said it still expected full-year revenue of $9.9 billion US to $10.1 billion US and adjusted earnings of $6.60 to $7.00 per share.

Source: CBC News August 09, 2016 12:44 UTC